Latest Period
Q1 2026
Security Snapshot
Annovis Bio, Inc. - Common Stock, par value $0.0001 per share (ANVS) Institutional Ownership
CUSIP: 03615A108
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
55
Shares (Excl. Options)
4,722,030
Price
$2.23
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- ANVS on NYSE
- Shares outstanding
- 19,607,843
- Price per share
- $1.84
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 4,722,030
- Total reported value
- $10,526,305
- % of total 13F portfolios
- 0%
- Share change
- +412,232
- Value change
- +$232,177
- Number of holders
- 55
- Price from insider filings
- $1.84
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- ANVS - Annovis Bio, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 03615A108.
- 55 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 52 to 55 between Q4 2025 and Q1 2026.
- Reported value moved from $14,662,646 to $10,526,305.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 55 institutions filings for Q1 2026.
Security key
03615A108
Latest holder period
Q1 2026
13F holders
55
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
ANVS full holder history
Annovis Bio, Inc. SEC filings
Annovis Bio, Inc. company facts
Annovis Bio, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03615A108:
Significant Owners of Annovis Bio, Inc. - Common Stock, par value $0.0001 per share (ANVS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| CVI Investments, Inc. | 4.9% | -4% | $1,470,000 | 1,000,000 | 0% | CVI Investments, Inc. | 31 Mar 2025 |
As of 31 Mar 2026, 55 institutional investors reported holding 4,722,030 shares of Annovis Bio, Inc. - Common Stock, par value $0.0001 per share (ANVS). This represents 24% of the company’s total 19,607,843 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Annovis Bio, Inc. - Common Stock, par value $0.0001 per share (ANVS) together control 23% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP | 6.1% | 1,187,499 | +64% | 0% | $2,648,124 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 872,381 | 0% | 0% | $1,945,410 |
| TWO SIGMA INVESTMENTS, LP | 3.2% | 627,659 | +14% | 0% | $1,399,680 |
| RENAISSANCE TECHNOLOGIES LLC | 1.8% | 347,600 | 0% | $775,148 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 247,513 | +11% | 0% | $552,218 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.1% | 218,336 | -28% | 0% | $486,889 |
| NORTHERN TRUST CORP | 0.72% | 141,730 | +17% | 0% | $316,058 |
| BlackRock, Inc. | 0.71% | 139,533 | 0% | 0% | $311,159 |
| VANGUARD FIDUCIARY TRUST CO | 0.67% | 132,042 | 0% | 0% | $294,454 |
| Merit Financial Group, LLC | 0.41% | 81,316 | 0% | 0% | $181,335 |
| STATE STREET CORP | 0.4% | 77,735 | +5% | 0% | $173,349 |
| GROUP ONE TRADING LLC | 0.36% | 69,663 | +0.78% | 0.01% | $155,348 |
| Sherry Group, Inc. | 0.29% | 57,270 | +110% | 0.14% | $127,712 |
| Greenwich Wealth Management LLC | 0.24% | 47,000 | +11% | 0% | $105,000 |
| GSA CAPITAL PARTNERS LLP | 0.23% | 45,423 | 0.01% | $101,000 | |
| Wescott Financial Advisory Group, LLC | 0.21% | 41,607 | 0% | 0.01% | $92,784 |
| First National Trust Co | 0.2% | 40,000 | 0% | 0% | $89,200 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.19% | 37,677 | +54% | 0% | $84,020 |
| Dakota Wealth Management | 0.13% | 26,000 | -0.76% | 0% | $57,980 |
| XTX Topco Ltd | 0.13% | 24,580 | 0% | $54,813 | |
| Sterling Investment Advisors, Ltd. | 0.12% | 23,416 | 0% | 0.01% | $52,218 |
| UBS Group AG | 0.11% | 21,538 | -30% | 0% | $48,030 |
| HRT FINANCIAL LP | 0.11% | 21,187 | 0% | $47,000 | |
| Wealthspire Advisors, LLC | 0.1% | 20,000 | 0% | 0% | $44,600 |
| Robertson Stephens Wealth Management, LLC | 0.09% | 18,579 | 0% | 0% | $41,431 |
Institutional Holders of Annovis Bio, Inc. - Common Stock, par value $0.0001 per share (ANVS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,722,030 | $10,526,305 | +$232,177 | $2.23 | 55 |
| 2025 Q4 | 4,237,986 | $14,662,646 | +$8,024,097 | $3.46 | 52 |
| 2025 Q3 | 2,024,516 | $4,189,707 | +$428,194 | $2.07 | 42 |
| 2025 Q2 | 1,811,877 | $3,929,691 | -$326,377 | $2.17 | 42 |
| 2025 Q1 | 2,086,860 | $3,130,127 | -$507,485 | $1.50 | 43 |
| 2024 Q4 | 1,575,712 | $7,926,263 | +$1,704,856 | $5.03 | 40 |
| 2024 Q3 | 1,179,026 | $9,503,457 | +$1,923,073 | $8.06 | 35 |
| 2024 Q2 | 984,218 | $5,669,358 | -$2,073,596 | $5.76 | 29 |
| 2024 Q1 | 1,190,821 | $14,170,568 | -$404,974 | $11.90 | 29 |
| 2023 Q4 | 1,204,452 | $22,522,950 | +$2,419,829 | $18.70 | 35 |
| 2023 Q3 | 1,111,889 | $10,551,231 | -$1,631,804 | $9.49 | 28 |
| 2023 Q2 | 1,278,556 | $18,270,029 | +$7,489,629 | $14.29 | 27 |
| 2023 Q1 | 752,202 | $11,588,203 | +$250,861 | $15.41 | 22 |
| 2022 Q4 | 736,307 | $9,887,632 | +$230,554 | $13.43 | 21 |
| 2022 Q3 | 718,857 | $9,847,000 | -$399,073 | $13.70 | 20 |
| 2022 Q2 | 770,387 | $8,735,000 | -$1,477,097 | $11.33 | 24 |
| 2022 Q1 | 888,924 | $11,867,000 | -$3,780,511 | $13.35 | 22 |
| 2021 Q4 | 1,115,969 | $19,619,000 | -$2,600,801 | $17.58 | 29 |
| 2021 Q3 | 1,140,634 | $36,227,000 | -$24,730,573 | $31.74 | 36 |
| 2021 Q2 | 1,272,982 | $108,947,000 | +$39,294,497 | $85.59 | 56 |
| 2021 Q1 | 834,363 | $23,108,000 | +$2,874,108 | $27.90 | 29 |
| 2020 Q4 | 759,911 | $5,730,000 | +$93,763 | $7.55 | 12 |
| 2020 Q3 | 315,551 | $1,518,000 | +$388,364 | $4.81 | 11 |
| 2020 Q2 | 243,843 | $1,060,000 | +$220,698 | $4.35 | 8 |
| 2020 Q1 | 192,761 | $580,000 | +$580,000 | $3.01 | 6 |